Therapeuticsmd Stock Today
| TXMD Stock | USD 0.77 0.04 5.48% |
PerformanceVery Weak
| Odds Of DistressHigh
|
TherapeuticsMD is trading at 0.77 as of the 18th of March 2025, a 5.48 percent increase since the beginning of the trading day. The stock's lowest day price was 0.72. TherapeuticsMD has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of December 2003 | Category Healthcare | Classification Health Care |
TherapeuticsMD, Inc. operates as a womens healthcare company in the United States. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Therapeuticsmd operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 11.53 M outstanding shares of which 155.75 K shares are at this time shorted by private and institutional investors with about 0.3 trading days to cover. More on TherapeuticsMD
Moving together with TherapeuticsMD Stock
Moving against TherapeuticsMD Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
TherapeuticsMD Stock Highlights
| Co-Founder, CEO and Director | Robert Finizio | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsTherapeuticsMD can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TherapeuticsMD's financial leverage. It provides some insight into what part of TherapeuticsMD's total assets is financed by creditors.
| |||||
TherapeuticsMD (TXMD) is traded on NASDAQ Exchange in USA. It is located in 951 Yamato Road, Boca Raton, FL, United States, 33431 and employs 1 people. TherapeuticsMD is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.36 M. TherapeuticsMD conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 11.53 M outstanding shares of which 155.75 K shares are at this time shorted by private and institutional investors with about 0.3 trading days to cover.
TherapeuticsMD currently holds about 27.08 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check TherapeuticsMD Probability Of Bankruptcy
Ownership Allocation30% of TherapeuticsMD outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check TherapeuticsMD Ownership Details
TherapeuticsMD Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ameriprise Financial Inc | 2024-12-31 | 22.5 K | |
| Northern Trust Corp | 2024-12-31 | 16.5 K | |
| J. Goldman & Co Lp | 2024-12-31 | 13.6 K | |
| Renaissance Technologies Corp | 2024-12-31 | 10.9 K | |
| Fmr Inc | 2024-12-31 | 8.3 K | |
| Tower Research Capital Llc | 2024-12-31 | 4.8 K | |
| Ubs Group Ag | 2024-12-31 | 2 K | |
| Group One Trading, Lp | 2024-12-31 | 1.1 K | |
| Bank Of America Corp | 2024-12-31 | 494 | |
| Rubric Capital Management Lp | 2024-12-31 | 1.2 M | |
| Clearline Capital Lp | 2024-12-31 | 635.2 K |
TherapeuticsMD Historical Income Statement
TherapeuticsMD Stock Against Markets
TherapeuticsMD Corporate Management
| Hugh MBA | Pres Director | Profile | |
| MD FACOG | CoFounder,CoCEO Officer | Profile | |
| Douglas Steelman | Vice Access | Profile | |
| Benjamin Foulk | Vice Resources | Profile | |
| Dedra Lyden | Vice Initiatives | Profile | |
| Joseph Ziegler | Principal Officer | Profile | |
| Daniella Silva | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TherapeuticsMD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TherapeuticsMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.35) | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets | Return On Equity |
The market value of TherapeuticsMD is measured differently than its book value, which is the value of TherapeuticsMD that is recorded on the company's balance sheet. Investors also form their own opinion of TherapeuticsMD's value that differs from its market value or its book value, called intrinsic value, which is TherapeuticsMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TherapeuticsMD's market value can be influenced by many factors that don't directly affect TherapeuticsMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.